Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Microcap & Penny Stocks : CardioDynamics (CDIC) -- Ignore unavailable to you. Want to Upgrade?

To: David Wiggins who wrote (70)	10/20/1999 7:33:00 AM
From: David Wiggins	Read Replies (1) \| Respond to of 201

GE Marquette Medical Systems and CardioDynamics International Announce Second Phase of Strategic Alliance SAN DIEGO--(BW HealthWire)--Oct. 20, 1999--GE Marquette Medical Systems (NYSE:GE - news) and CardioDynamics International Corporation (Nasdaq:CDIC - news), today announced that the companies have signed a U.S. hospital distribution agreement, expanding their European distribution agreement announced in August. The agreement provides GE Marquette exclusive rights to market and sell CardioDynamics' BioZ® noninvasive digital cardiac output monitoring systems to hospitals in the U.S. CardioDynamics' direct sales force, specialized in out-of-hospital sales, will continue to sell the BioZ product line to physician offices, where they have been highly effective. The companies will be jointly exhibiting the BioZ Systems at the American Heart Association Session Nov. 8-11, 1999, in Atlanta. Commenting on the agreement, Kevin King, vice president of Global Marketing, GE Marquette Medical Systems, stated, ''It is very exciting to expand our European distribution relationship with CardioDynamics to include hospitals in the U.S. This is an area where GE Marquette is well-established, and we expect the leading-edge clinical capabilities of the BioZ Systems to be welcomed by U.S. healthcare providers. ''The BioZ Systems can help healthcare providers improve the quality of care and lower the cost of treatment by supporting a noninvasive assessment of cardiovascular function.'' ''CardioDynamics has built a core competency in selling to physician offices and outpatient heart failure clinics, and this latest agreement with GE Marquette should drive incremental business through increased penetration of our BioZ Systems into U.S. hospitals,'' stated Michael K. Perry, CEO of CardioDynamics. ''GE Marquette has a significant presence in the U.S. and is strongly recognized globally for its leading technologies in the areas of diagnostic cardiology, clinical information systems, and patient monitoring equipment. ''The agreement capitalizes on GE Marquette's established relationships and expands our sales presence ten-fold in the U.S. hospital marketplace. This alliance provides a solid foundation to significantly grow sales of our proprietary technology and establish the BioZ's measurement capabilities as the Sixth Vital Sign(TM),'' added Perry. CardioDynamics, with headquarters in San Diego, is committed to fundamentally changing the way hemodynamic monitoring is performed in healthcare. The company's primary products, the BioZ® System, Portable BioZ(TM) and BioZ.com(TM), utilize its proprietary Thoracic Electrical Bioimpedance (TEB) technology to noninvasively obtain data on a wide range of hemodynamic parameters. The worldwide market potential for the BioZ® products is estimated to be $4 billion, together with an additional $800 million in recurring annual revenue for disposables. For additional information, please refer to the company's web site at www.cardiodynamics.com.

To: David Wiggins who wrote (70)	10/16/2000 12:07:22 AM
From: wolfdog2	Read Replies (1) \| Respond to of 201

David, the BW article called my attention to this company. Only negative that I can see is the sizeable number of insider sales reported as of the close of business Friday by InsiderTrader.com. I'm going to pick up some shares on Monday despite the insider selling, however. My research indicates that management is not particularly well paid and they may simply seeing selling shares as part of their remuneration. If you like this company, then I suggest you take a look at DFIB, which, though not a competitor of CDIC, is in the same space. By the way there has been insider buying in DFIB.